Slides
Page 1
Earnings Presentation August 2025
Page 2
Disclaimer 2 Akums Drugs and Pharmaceuticals Limited may, from time to time, make written and oral forward-looking statements, in addition to statements contained in the company's filings with BSE Limited (BSE) and National Stock Exchange of India Limited (NSE), and its reports to shareholders. The company does not undertake to update any forward-looking statements that may be made from time to time by or on behalf of the Akums Drugs and Pharmaceuticals Limited. All information contained in this presentation has been prepared solely by Akums Drugs and Pharmaceuticals Limited. Akums Drugs and Pharmaceuticals Limited does not accept any liability whatsoever for any loss, howsoever, arising from any use or reliance on this presentation or its contents or otherwise arising in connection therewith.
Page 3
Managing Directors’ Message Dear Investors We are pleased to declare the Q1 results for FY 26. This date marks just over one year since we began our journey as a listed company. We continue to work towards strengthening the organization with a focus on long term growth. The long-term growth prospects of the company remain intact with growth in both revenues and profitability. R&D remains the back bone of the company. We achieved the milestone of 1,000 DCGI approvals. During this quarter we received 27 DCGI approvals as against 31 approvals for the entire last year. As part ofAkums’ strategic vision to establish itself as a leading global CDMO, we received our first EU dossier approval for Rivaroxaban. We also filed our first dossier of Dapagliflozin combination in Switzerland. Both of these new products hold significant market potential. The commercialization of the EU contract continues to be on track. We will commence commercial supplies from April 2027. As informed during the last call, Akums had received 100 mn Euros as part consideration for the EU contract in this quarter, consequently our cash surplus now stands at INR 1,518 cr. The strong liquidity position provides a robust foundation for Akums to strategically scale up its business operations through both organic growth initiatives and inorganic opportunities. The first quarter of FY26 continued to see tepid volume growth, with market volume growth below 0.5% and IPM growth being driven largely by price growth. The weakness in API pricing continues. Looking ahead, we remain focused on strengthening our CDMO leadership, scaling high-value capabilities, and driving operational excellence. Backed by a strong pipeline and prudent capital allocation, we are well-positioned to deliver sustainable and profitable growth in the years ahead. - Sanjeev Jain & Sandeep Jain 3
Page 4
Incorporated in April 2004 Set up of first plant for oral solid dosage form in Haridwar. Established dedicated manufacturing site for Oral Liquid Dosage & Sterile products. Established a nutraceutical facility Expanded into Asian markets. Established R&D lab in Mumbai to venture into regulated market. Received US-NSF Certification for Maxcure Nutravedicsfacility Dedicated facilities for Hormones, Cosmetics and Dermatology. Launched Akumentisto venture into branded formulations. Started dedicated plant for β-lactam anti- infectives and steroids Quadria Capital bought a minority stake in the company Acquired Parabolic Drugs to venture intoAPI Plant 1 & Plant 3 accredited by EU-GMP thusqualifying for European exports Listed on NSE and BSE Started new injectable facility ANVISA certified for Plant 3 Two Decades’ Legacy of Expertise, Experience & Trust 2004 2010 2021Build Strengthen Accelerate 2025 4
Page 5
Location 5 Technologically Advanced Manufacturing Capabilities Haridwar Haridwar Haridwar Haridwar Haridwar Haridwar Haridwar Haridwar Kotdwar Baddi Haridwar Year 2004 2007 2007 2010 2010 2010 2014 2014 2021 2023 2024 Annual Capacity (Cr units) 649 15 39 244 6 252 2.603 732 17 368 36 Capability General General General Hormonal Cosmetics Ayurvedic / Nutraceuticals General β-lactams and steroids Penem anti-infective General General Dosage Forms 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 32 4Oral Solid Oral Liquid Injectable / Sterile External / Topical Key Accreditations* *Received by some or all facilities;
Page 6
R&D Focus Innovative In-house Technologies Inlay Tablet Multiple Tablets in Capsule Smart Tablets Gummies Mouth Melting Powders in Sachet Tri Layered Tablet Tablet In Tablet Bi-layered, Sustained Release Tablet in Tablet 6(1) As of 31st March 2025 Lyophilized Vials Pre-filled syringes Illustrative
Page 7
Key Highlights 7 1,518 Cr. Cash Surplus (566 Cr in FY25) 1,000 DGCI Approvals (+27 in Q1FY26) € 100 Mn Received as advance against European CDMO contract Zero Liquid Discharge (ZLD) implemented across 5 plants Brazil ANVISA approval for Plant 3 and Russia GMP granted in Plant 4 20 New Approvals including 1st EU Approval (Rivaroxaban) 44 Dossiers filed – 1st submission in Switzerland, Iraq, and Jordan Strengthened senior leadership teams in IT, Finance and Strategy
Page 8
Financial Performance Highlights Q1 FY 26 8
Page 9
Consolidated Performance Highlights 9 Business Vertical Share in Q1 FY26 revenue CDMO 79.4% Domestic Branded Formulation 10.5% API 4.4% International Branded Formulation 3.4% Trade Generics 2.3% Segment Break-upQ1 FY26 1,051 cr Total Income (+2.4% YoY) 156 cr 14.8% Adj. EBITDA (+208 bps YoY) 65 cr 6.2% Adj. PAT (+57 bps YoY) (Adjusted EBITDA = Profit before tax + fair value changes to financial instrument + finance cost + depreciation and amortizat ion ; Adjusted PAT = PAT + Fair value changes to financial instrument
Page 10
Consolidated Quarterly Performance Highlights (1) Adjusted EBITDA = Profit before tax + fair value changes to financial instrument + finance cost + depreciation and amorti zation ; (2) Adjusted PAT = PAT + Fair value changes to financial instrument - deferred tax created on brought forward losses (INR 106 cr) in Q4 FY 25) Total Income (INR Cr.) Adjusted EBITDA1 (INR Cr) 13.3%12.9% Margin % 10.4% 14.8%12.7% 156 111 136 135 131 Q1 FY 26Q4 FY 25Q3 FY 25Q2 FY 25Q1 FY 25 Adjusted PAT2 (INR Cr) 6.5%6.4% Margin % 4.1% 6.2%5.6% 65 44 66 67 57 Q1 FY 26Q4 FY 25Q3 FY 25Q2 FY 25Q1 FY 25 10 2.4% 19.1% 12.8 % 1,051 1,073 1,025 1,047 1,026 Q1 FY 26Q4 FY 25Q3 FY 25Q2 FY 25Q1 FY 25
Page 11
Revenue and Margin Breakdown 11 Total Income (INR Cr.) Adj EBIDTA % CDMO Revenue (INR Cr.) 6.6% Adjusted EBITDA = Profit before tax + fair value changes to financial instrument + finance cost + depreciation and amortizati on • CDMO growth slow on account of declining API prices and muted volume growth • Trade Generics and API sales decline as focus was on to minimize losses • Improved gross margins driven by continued focus on niche products. • Other expenses driven by increased power and fuel costs and provisions. • Despite dip in API prices as well as muted volume growth, CDMO segment grew led by improved product mix
Page 12
12 Segmental Quarterly Performance CDMO Revenue Domestic Branded Formulation Revenue International Branded Formulation Revenue Trade generics Revenue API Revenue CDMO EBITDA 10.6%15.5% 14.7% Margin % Trade generics EBITDA API EBITDA Domestic Branded Formulation EBITDA 12.9% 21.6% 14.7% International Branded Formulation EBITDA 21.7% 22.1% 23.0% 782 840 813 Q1 FY 25 Q4 FY 25 Q1 FY 26 104 104 107 Q1 FY 25 Q4 FY 25 Q1 FY 26 34 40 35 Q1 FY 25 Q4 FY 25 Q1 FY 26 121 89 119 Q1 FY 25 Q4 FY 25 Q1 FY 26 29 22 23 Q1 FY 25 Q4 FY 25 Q1 FY 26 13 22 16 Q1 FY 25 Q4 FY 25 Q1 FY 26 70 50 45 Q1 FY 25 Q4 FY 25 Q1 FY 26 7 9 8 Q1 FY 25 Q4 FY 25 Q1 FY 26 -4 -10 -5 Q1 FY 25 Q4 FY 25 Q1 FY 26 -12 -6 -6 Q1 FY 25 Q4 FY 25 Q1 FY 26 4.0%YoY-3.1%QoQ 3.4%YoY3.7%QoQ 2.4%YoY-11.7%QoQ -20.9%YoY3.8%QoQ -35.4%YoY-10.2%QoQ
Page 13
Objects of the offer 13 Objects (INR Cr) Amount as per offer document Utilization as on June 30, 2025 Unutilized Amount Repayment borrowings of Akums 159.91 159.91 - Repayment of borrowings of our Subsidiaries 227.09 227.09 - Funding incremental working capital requirements of our Company 55.00 55.00 - Pursuing inorganic growth initiatives through acquisitions 27.87 27.87 - General corporate purposes 167.50 167.50 -
Page 14
Thank You For further information, contact: 14 Siddharth Rangnekar / Shruti Joshi CDR, India Tel: +91 97699 19966 / 75065 67349 Email: siddharth@cdr-india.com / shruti@cdr-india.com IR Desk Akums Drugs and Pharmaceuticals Ltd Email: investors@akums.net/ankit.jain@akums.net